Transcription of Interagency Guideline on Prescribing Opioids for Pain
{{id}} {{{paragraph}}}
Interagency Guideline on Prescribing Opioids for Pain Developed by the Washington State Agency Medical Directors Group (AMDG) in collaboration with an Expert Advisory Panel, Actively Practicing Providers, Public Stakeholders, and Senior State Officials. Written for Clinicians who Care for People with Pain 3rd Edition, June 2015 Interagency Guideline on Prescribing Opioids for Pain [06-2015] 2 Table of Contents A MESSAGE FROM WASHINGTON S SECRETARY OF HEALTH .. 4 COMPARISON OF 2010-2015 GUIDELINES .. 5 INTRODUCTION .. 6 Correct Diagnosis and Realistic Expectations .. 6 Uncertain Long-term Efficacy, Clear Evidence of Harm.. 7 Opioids and Chronic Disability .. 8 PART I. RECOMMENDATIONS FOR ALL PAIN PHASES .. 9 Clinically Meaningful Improvement in Function (CMIF) .. 9 Dosing Threshold .. 11 Non-opioid Options for Pain Management .. 14 PART II. Prescribing Opioids IN THE ACUTE AND SUBACUTE PHASE .. 22 Opioids in the Acute Phase.
Effective treatment of pain begins with an accurate diagnosis. Beyond the acute injury, the underlying cause of ongoing pain can be difficult to identify.
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}
Opioid Related Neonatal Abstinence Syndrome, Opioid Related Neonatal Abstinence Syndrome: Is Clonidine, Neonatal abstinence syndrome, Managing, Preventing and Addressing Neonatal Abstinence Syndrome, Managing Abstinence, Impact of Addiction on Infant Mortality, Objectives What is NAS, Neonatal, Syndrome, Reduce Severity of Neonatal Abstinence Syndrome, Abstinence syndrome, PUBLIC HEALTH INTERVENTIONS FOR NEONATAL ABSTINENCE SYNDROME, Modified Finnegan Neonatal Abstinence Score, Neonatal Abstinence Syndrome: Time for